Healthy Skepticism Library item: 13472

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Trotta F, Apolone G, Garattini S, Tafuri G.
Stopping a trial early in oncology: for patients or for industry?
Annals of Oncology 2008 Apr 9; epub ahead of print
http://annonc.oxfordjournals.org/cgi/content/full/mdn042v4

Abstract:

Background: The aim of this study is to assess the use of interim analyses in randomised controlled trials (RCTs) testing new anticancer drugs, focussing on oncological clinical trials stopped early for benefit.

Materials and methods: All published clinical trials stopped early for benefit and published in the last 11 years, regarding anticancer drugs and containing an interim analysis, were assessed.

Results: Twenty-five RCTs were analysed. The evaluation of efficacy was protocol planned through time-related primary end points, >40% of them overall survival. In 95% of studies, at the interim analysis, efficacy was evaluated using the same end point as planned for the final analysis. As a consequence of early stopping after the interim analysis, 3300 patients/events across all studies were spared. More than 85% of the RCTs published in the last 3 years were used for registration purposes.

Conclusion: Though criticism of the poor quality of oncological trials seems out of place, unfortunately early termination raises new concerns. The relation between sparing patients and saving time and trial costs indicates that there is a market-driven intent. We believe that only untruncated trials can provide a full level of evidence which can be translated into clinical practice without further confirmative trials.

g.tafuri@aifa.gov.it

Keywords:
anticancer drugs, EMEA, FDA, end point, interim analysis, RCT

Notes:

Free full text